Use of a levonorgestrel-releasing intrauterine device in the treatment of adenomyosis associated heavy menstrual bleeding

Uysal A, Ahmet Uysal, Cüneyt Eftal Taner, Taner CE, Mun S, Semih Mun, Uysal F, Fatma Uysal, Fatma Horasan Çelimli, Fatma Horasan Celimli, Celimli FH
JPMA. The Journal of the Pakistan Medical Association · 2013 · vol. 63(11) , pp. 1349–52 · PMID:24392517 · W313189915
Other OA: closed CC0 ⤵ 8 in-corpus citations
View on OpenAlex View on PubMed
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This study evaluated a levonorgestrel-releasing intrauterine device for adenomyosis-associated heavy menstrual bleeding, finding amenorrhea or regular menses in most patients by 12 months with improved hemoglobin and reduced endometrial thickness.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To evaluate the effects of a levonorgestrel-releasing intrauterine device in the treatment of adenomyosis associated with heavy menstrual bleeding. METHODS: The retrospective study was conducted at a tertiary referral hospital in Izmir, Turkey, and comprised data on adenomyosis patients who were implanted with a levonorgestrel-releasing intrauterine device for heavy menstrual bleeding between December 2004 and January 2008. After the insertion of the device, all patients were followed up by transvaginal ultrasonography and serum haemoglobin levels and menstrual patterns were determined at the 6th and 12th month. Data was analysed using SPSS 10. RESULTS: The mean age of the 42 women in the study was 43.2 +/- 0.8 years. At the sixth month, amenorrhoea, oligomenorrhoea, spotting and regular menstrual flow were 9.5% (n = 4), 7% (n = 3), 19% (n = 8), and 64% (n = 27), respectively. At the 12th month, the same parametres were 9.5% (n = 4), 7% (n = 3), 12% (n = 5), and 71% (n = 30), respectively. Haemoglobin levels had increased and endometrial thickness had decreased, and these differences were statistically significant (p < 0.001). CONCLUSION: The easy-to-use levonorgestrel-releasing intrauterine device can be added to the treatment options as a well-tolerated alternative in cases where a woman who has completed her fertility and does not request a hysterectomy has anaemia associated with adenomyosis.

My notes (saved in your browser only)

Condition tags

adenomyosis

MeSH descriptors

Adenomyosis Contraceptive Agents, Female Intrauterine Devices, Medicated Intrauterine Devices, Medicated Levonorgestrel Menorrhagia Menorrhagia Adenomyosis Adenomyosis Adult Adult Contraceptive Agents, Female Contraceptive Agents, Female Female Female Humans Humans Levonorgestrel Levonorgestrel Menorrhagia

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (16)

Cited by (8)

Source provenance

europepmc
last seen: 2026-10-14T06:08:39.101224+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:13:06.373426+00:00
License: CC0 · commercial use OK